作者: Yutaka Yonemura , Yoshio Endou , Masaya Shinbo , Takuma Sasaki , Masamitu Hirano
DOI: 10.1002/JSO.21324
关键词:
摘要: There is no standard treatment for peritoneal carcinomatosis (PC) from gastric cancer. New bidirectional chemotherapy (neoadjuvant intraperitoneal-systemic protocol (NIPS)) was developed. The aim of the present study to assess safety and efficacy NIPS show selection cytoreductive surgery on PC Seventy-nine patients with cancer were treated NIPS. A port system introduced into abdominal cavity. wash cytological examination through a done before after oral TS-1 twice daily 21 days, followed by 1-week rest. On day 1, 8, 15 start administration, 30 mg/m(2) Docetaxel cisplatinum 500 ml saline cavity port. median course 2.1 time IP chemoterapy 5.8. Peritoneal free cells (PFCCs) had been detected in 65 (82.2%) NIPS, positive cytology changed be negative 41 (63.0%) After underwent laparotomy, complete cytoreduction 32 (78%) patients. Complete 27 (51.9%) 52 but only 4 (14.8%) (P < 0.001). Patients survived significantly longer than those cytology. adverse effects mild there treatment-related deaths. grade 3/4 hematological found 2 (2.6%) Grade 3 renal toxicity site infection three patients, respectively. using safe effective PC. good indicator select perform surgery.